| 10.24.3* | Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Agreement under 2023 Equity Incentive Plan. | 8-K | 001-40427 | 10.24.3 | October 5, 2023 | |||||
| 10.25* | NKGen Biotech, Inc. 2023 Employee Stock Purchase Plan. | 8-K | 001-40427 | 10.25 | October 5, 2023 | |||||
| 10.26* | Form of Indemnification Agreement by and between NKGen Biotech, Inc. and its directors and executive officers. | 8-K | 001-40427 | 10.26 | October 5, 2023 | |||||
| 10.27 | Amendment to Forward Purchase Agreement, dated as of December 26, 2023, among NKGen and Meteora Capital Partners, LP and certain of its affiliates. | 8-K | 001-40427 | 10.1 | December 27, 2023 | |||||
| 10.28 | Second Amendment to Forward Purchase Agreement, dated as of January 2, 2024, among NKGen and Meteora Capital Partners, LP and certain of its affiliates. | 8-K | 001-40427 | 10.1 | January 8, 2024 | |||||
| 10.29 | Third Amendment to Forward Purchase Agreement, dated as of January 11, 2024, among NKGen and Meteora Capital Partners, LP and certain of its affiliates. | 8-K | 001-40427 | 10.1 | January 11, 2024 | |||||
| 10.30 | Amendment to Forward Purchase Agreement, dated as of January 19, 2024, among NKGen and Sandia Investment Management LP on behalf of the investors thereto. | 8-K | 001-40427 | 10.1 | January 22, 2024 | |||||
| 10.31 | Term Sheet, entered into on February 9, 2024, between the Company and Meteora. | 8-K | 001-40427 | 10.1 | February 12, 2024 | |||||
| 10.32 | Fourth Amendment to Forward Purchase Agreement, dated as of February 21, 2024, among NKGen and Meteora Capital Partners, LP and certain of its affiliates. | 8-K | 001-40427 | 10.1 | February 22, 2024 | |||||
| 10.33 | Promissory Note issued to FirstFire, dated March 21, 2024. | 8-K | 001-40427 | 10.1 | March 27, 2024 | |||||
| 10.34+ | Securities Purchase Agreement, dated March 21, 2024, by and between FirstFire and the Company. | 8-K | 001-40427 | 10.2 | March 27, 2024 | |||||
| 10.35 | Promissory Note issued to Meteora, dated March 26, 2024. | 8-K | 001-40427 | 10.3 | March 27, 2024 | |||||
| 10.36+ | Securities Purchase Agreement, dated March 26, 2024, by and among Meteora and the Company. | 8-K | 001-40427 | 10.4 | March 27, 2024 | |||||
| 10.37 | Promissory Note issued to AJB, dated April 1, 2024. | 8-K | 001-40427 | 10.1 | April 5, 2024 | |||||
| 10.38+ | Securities Purchase Agreement, dated April 1, 2024, by and between AJB and the Company. | 8-K | 001-40427 | 10.2 | April 5, 2024 | |||||
| 10.39 | Promissory Note issued to Sandia, dated April 1, 2024. | 8-K | 001-40427 | 10.3 | April 5, 2024 | |||||
| 10.40+ | Securities Purchase Agreement, dated April, 2024, by and among Sandia and the Company. | 8-K | 001-40427 | 10.4 | April 5, 2024 | |||||
| 10.41 | Equity and Business Loan Agreement, dated April 5, 2024, by and among NKGen Biotech, Inc., NKGen Operating Biotech, Inc. and BDW Investments LLC. | 8-K | 001-40427 | 10.1 | April 11, 2024 |
| 10.10# | Promissory Note issued by NKGen Biotech, Inc. to Lisa J. Ling, dated September 5, 2023. | 8-K | 001-40427 | 10.10 | October 5, 2023 | |||||
| 10.11.1* | Amended and Restated License Agreement dated April 10, 2023, by and between NKGen and NKMAX. | S-4/A | 333-271929 | 10.15.1 | August 4, 2023 | |||||
| 10.11.2* | Amendment to the Amended and Restated License Agreement dated August 1, 2023, by and between NKGen and NKMAX. | S-4/A | 333-271929 | 10.15.2 | August 4, 2023 | |||||
| 10.12.1* | NKGen Biotech, Inc. 2019 Equity Incentive Plan. | S-4/A | 333-271929 | 10.13 | June 26, 2023 | |||||
| 10.12.2* | Form of Stock Option Agreement under NKGen Biotech, Inc. 2019 Equity Incentive Plan. | S-4/A | 333-271929 | 10.14.1 | June 26, 2023 | |||||
| 10.12.3* | Form of Stock Option Grant Notice under NKGen Biotech, Inc. 2019 Equity Incentive Plan. | S-4/A | 333-271929 | 10.14.2 | June 26, 2023 | |||||
| 10.13.1#+ | Business Loan Agreement, as amended and supplemented, dated June 20, 2023, by and between NKGen Biotech, Inc. and East West Bank. | S-4/A | 333-271929 | 10.16 | August 4, 2023 | |||||
| 10.13.2# | Amendment to the Business Loan Agreement, dated September 19, 2023, by and between NKGen Biotech, Inc. and East West Bank. | 8-K | 001-40427 | 10.13.2 | October 5, 2023 | |||||
| 10.14 | Loan Agreement, dated January 6, 2023, by and between NKGen and NKMAX. | S-4/A | 333-271929 | 10.17.1 | August 4, 2023 | |||||
| 10.15 | Loan Agreement, dated January 18, 2023, by and between NKGen and NKMAX. | S-4/A | 333-271929 | 10.17.2 | August 4, 2023 | |||||
| 10.16 | Loan Agreement, dated February 3, 2023, by and between NKGen and NKMAX. | S-4/A | 333-271929 | 10.17.3 | August 4, 2023 | |||||
| 10.17 | Loan Agreement, dated February 28, 2023, by and between NKGen and NKMAX. | S-4/A | 333-271929 | 10.17.4 | August 4, 2023 | |||||
| 10.18 | Loan Agreement, dated March 20, 2023, by and between NKGen and NKMAX. | S-4/A | 333-271929 | 10.17.5 | August 4, 2023 | |||||
| 10.19.1* | Offer Letter, dated January 1, 2020, by and between Sangwoo Park and NKGen. | S-4/A | 333-271929 | 10.19.1 | August 4, 2023 | |||||
| 10.19.2* | Amended and Restated Offer Letter, dated December 28, 2022, by and between Sangwoo Park and NKGen Biotech, Inc. | S-4/A | 333-271929 | 10.19.2 | August 4, 2023 | |||||
| 10.20*# | Offer Letter, dated December 26, 2022, by and between Paul Y. Song and NKGen Biotech, Inc. | S-4/A | 333-271929 | 10.18 | August 4, 2023 | |||||
| 10.21*# | Offer Letter, dated December 15, 2019 by and between Yong Man Kim and NKMAX Co. Ltd. | S-4/A | 333-271929 | 10.21 | August 4, 2023 | |||||
| 10.22*# | Offer Letter, dated October 15, 2021, by and between Pierre Gagnon and NKGen Biotech, Inc. | S-4/A | 333-271929 | 10.20 | August 4, 2023 | |||||
| 10.23*# | Offer Letter, dated September 29, 2023 by and between James A. Graf and NKGen Biotech, Inc. | 8-K | 001-40427 | 10.23 | October 5, 2023 | |||||
| 10.24.1* | NKGen Biotech, Inc. 2023 Equity Incentive Plan. | 8-K | 001-40427 | 10.24.1 | October 5, 2023 | |||||
| 10.24.2* | Form of Stock Option Grant Notice and Form of Stock Option Agreement under 2023 Equity Incentive Plan. | 8-K | 001-40427 | 10.24.2 | October 5, 2023 |
